MetaCap

Q32 Bio Inc. (QTTB)

NASDAQ: QTTBHealth CareBiotechnology: Pharmaceutical PreparationsUSD

8.34-0.14 (-1.65%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

QTTB stock chart

Technical analysis

Key statistics

All statistics
Market cap
$249.57M
52-week range
1.98 – 23.57
Day range
8.23 – 8.59
Volume / Avg
476.72K / 692.58K
Beta
—

52-week range

$1.98$23.57

QTTB stock today

On Nov 20, QTTB ended the session at $8.34, shedding $0.14 (1.65%), versus the S&P 500's 3.70% decline. Shares are 64.6% below their 52-week high of $23.57, set on Jul 14, 2026 and 321.2% above the 52-week low of $1.98, in the middle of the past year's range. QTTB is up 151.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 317.0%.

Q32 Bio trades at 2.3x its trailing twelve-month earnings per share of $3.60.

Summary generated from market data by MetaCap's automated system. Methodology

About Q32 Bio

Company profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Jodie Pope Morrison
Headquarters
Waltham, MA
Employees
25
IPO year
2018
Website
q32bio.com

Financial highlights

Full financials

In fiscal 2025, Q32 Bio generated $53.7 million in revenue, up 0.0% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $29.8 million, for a net margin of 55.5% versus a median of -219.0% in the prior 5 years. Operating margin was 31.5%.

Q32 Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$53.74M$0$-6.65M$3.21M$33.97M
Growth—+100.00%-307.33%-90.56%+1157.25%
Net income$29.82M$-47.73M$-53.74M$-5.00M$-95.76M
EPS (diluted)$2.42$-6.58$-153.96$-0.09$-1.73

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$39.67+375.66%

  • Strong buy 1
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $29.00High $59.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.26 vs $-0.36
Surprise
+27.78%

QTTB news

All QTTB news

Q32 Bio peers

Health Care sector
QTTB peer companies
CompanyPrice% ChgMarket capCompare
PRLDPrelude Therapeutics Incorporated3.23-0.77%$258.63Mvs QTTB
ALTAltimmune Inc.1.33-5.67%$258.80Mvs QTTB
EBSEmergent BioSolutions Inc.5.05-1.94%$259.65Mvs QTTB
TTRXTurn Therapeutics Inc.8.10-6.31%$247.49Mvs QTTB
VCREVicore Pharma Holding AB ADR9.41-5.09%$264.89Mvs QTTB
LFCRLifecore Biomedical Inc.6.39+0.31%$242.22Mvs QTTB
CAMPCAMP4 Therapeutics Corporation3.79-5.25%$237.84Mvs QTTB
GALTGalectin Therapeutics Inc.2.69-4.27%$271.35Mvs QTTB

Indexes, lists and sector

Q32 Bio stock FAQ

What is Q32 Bio's stock price today?

QTTB last traded at $8.34 as of Nov 20, 4:00 PM EST, down 1.65% on the day. Prices are delayed at least 15 minutes.

Does Q32 Bio pay a dividend?

No. Q32 Bio does not currently pay a regular cash dividend.

What is QTTB's P/E ratio?

QTTB trades at a trailing P/E ratio of 2.32.

Who is Q32 Bio's CEO?

Ms. Jodie Pope Morrison is the chief executive officer of Q32 Bio Inc., which has about 25 employees.

Has QTTB ever split its stock?

Yes. The most recent QTTB stock split was a 1-for-18 split on Mar 26, 2024.

What is the QTTB 52-week high?

The 52-week high for QTTB is $23.57 and the 52-week low is $1.98. The stock is currently 64.6% below its high.

Compare QTTB